港股異動 | 泰格醫藥AH股齊創新高 H股月內升幅近30%
格隆匯12月16日丨泰格醫藥AH股延續漲勢,H股月內升幅近30%。現漲5.13%,高見169港元再次破頂,總市值1502億港元。A股泰格醫藥收漲超5%,盤中再度刷新歷史高價。中銀國際報告,首予泰格醫藥H股目標價170港元,買入評級。在12月4日,H股獲NINETY ONE UK LIMITED在場內以每股均價146.255港元增持13.26萬股,涉資約1939.3萬港元。另外,招銀國際近日發佈研報稱泰格醫藥第三季度進一步復甦,給予A股146.43元的目標價。格隆匯APP顯示,H股近期亦獲南下資金高位加倉,港股通持倉比例升至0.52%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.